Pub Date : 2026-03-01Epub Date: 2025-10-20DOI: 10.1016/j.jchf.2025.102713
Jonathan D. Moreno MD, PhD , Douglas L. Mann MD
{"title":"Bringing Advanced Heart Failure Therapies to Veterans","authors":"Jonathan D. Moreno MD, PhD , Douglas L. Mann MD","doi":"10.1016/j.jchf.2025.102713","DOIUrl":"10.1016/j.jchf.2025.102713","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"14 3","pages":"Article 102713"},"PeriodicalIF":11.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145331705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-10-31DOI: 10.1016/j.jchf.2025.102759
Joshua A. Rushakoff MD, MPP , Adam D. DeVore MD, MHS , Adrian Hernandez MD, MHS , Richa Agarwal MD , Karen Flores Rosario MD , Jeffrey Keenan MD , Jacob N. Schroder MD , Carmelo A. Milano MD , Chetan B. Patel MD
{"title":"From Zero to Zero Sum","authors":"Joshua A. Rushakoff MD, MPP , Adam D. DeVore MD, MHS , Adrian Hernandez MD, MHS , Richa Agarwal MD , Karen Flores Rosario MD , Jeffrey Keenan MD , Jacob N. Schroder MD , Carmelo A. Milano MD , Chetan B. Patel MD","doi":"10.1016/j.jchf.2025.102759","DOIUrl":"10.1016/j.jchf.2025.102759","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"14 3","pages":"Article 102759"},"PeriodicalIF":11.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145411511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-10-10DOI: 10.1016/j.jchf.2025.102702
Ortal Tuvali MD , Rafael Kuperstein MD , Donna R. Zwas MD, MPH , Igor Volodarsky MD , Edi Vaisbuch MD , Sara Shimoni MD , Jacob George MD , Sorel Goland MD
Background
Data on the long-term clinical course of peripartum cardiomyopathy (PPCM) are limited.
Objectives
This study aims to evaluate the long-term outcomes of patients with PPCM.
Methods
The authors prospectively followed 119 women at 3 medical centers in Israel, of whom 96 had complete clinical and echocardiographic data and at least 3 years of follow-up observation and were included in the analysis.
Results
The mean age at diagnosis was 31.6 ± 6.4 years, and the median left ventricular ejection fraction (LVEF) at presentation was 38% (Q1-Q3: 30%-43%). Of these patients, 76% achieved left ventricular recovery (defined as LVEF ≥50%), with a median LVEF of 55% (Q1-Q3: 49%-60%) at 1 year. The median follow-up period was 9.0 years (Q1-Q3: 6.1-13.8 years), 83% of women were followed for at least 5 years, and 40% for more than 10 years. During follow-up, 2 patients died of noncardiac causes, and the cause of death was unknown in 1. At long-term follow-up, LVEF was 56% (Q1-Q3: 50%-60%). Among the patients with LV recovery, 5 patients showed a decline in LVEF, and 5 of 23 patients with persistent LV dysfunction achieved LV recovery during long-term follow-up. Forty-six percent of patients received ≥1 cardiovascular medications during 10 years of follow-up evaluation. Of the 56 patients with a median LVEF of 58% (Q1-Q3: 55%-60%) who had subsequent pregnancies, 51 patients had full-term deliveries. No significant reduction in LVEF or increased cardiovascular comorbidities was observed at long-term follow-up.
Conclusions
This study demonstrates favorable long-term outcomes in women with PPCM, low mortality, and stability of cardiac function. Subsequent pregnancies had no significant impact on their clinical course. During follow-up, cardiovascular comorbidities and medication use were documented for a substantial proportion of patients.
{"title":"Long-Term Outcomes in Women With a History of Peripartum Cardiomyopathy","authors":"Ortal Tuvali MD , Rafael Kuperstein MD , Donna R. Zwas MD, MPH , Igor Volodarsky MD , Edi Vaisbuch MD , Sara Shimoni MD , Jacob George MD , Sorel Goland MD","doi":"10.1016/j.jchf.2025.102702","DOIUrl":"10.1016/j.jchf.2025.102702","url":null,"abstract":"<div><h3>Background</h3><div>Data on the long-term clinical course of peripartum cardiomyopathy (PPCM) are limited.</div></div><div><h3>Objectives</h3><div>This study aims to evaluate the long-term outcomes of patients with PPCM.</div></div><div><h3>Methods</h3><div>The authors prospectively followed 119 women at 3 medical centers in Israel, of whom 96 had complete clinical and echocardiographic data and at least 3 years of follow-up observation and were included in the analysis.</div></div><div><h3>Results</h3><div>The mean age at diagnosis was 31.6 ± 6.4 years, and the median left ventricular ejection fraction (LVEF) at presentation was 38% (Q1-Q3: 30%-43%). Of these patients, 76% achieved left ventricular recovery (defined as LVEF ≥50%), with a median LVEF of 55% (Q1-Q3: 49%-60%) at 1 year. The median follow-up period was 9.0 years (Q1-Q3: 6.1-13.8 years), 83% of women were followed for at least 5 years, and 40% for more than 10 years. During follow-up, 2 patients died of noncardiac causes, and the cause of death was unknown in 1. At long-term follow-up, LVEF was 56% (Q1-Q3: 50%-60%). Among the patients with LV recovery, 5 patients showed a decline in LVEF, and 5 of 23 patients with persistent LV dysfunction achieved LV recovery during long-term follow-up. Forty-six percent of patients received ≥1 cardiovascular medications during 10 years of follow-up evaluation. Of the 56 patients with a median LVEF of 58% (Q1-Q3: 55%-60%) who had subsequent pregnancies, 51 patients had full-term deliveries. No significant reduction in LVEF or increased cardiovascular comorbidities was observed at long-term follow-up.</div></div><div><h3>Conclusions</h3><div>This study demonstrates favorable long-term outcomes in women with PPCM, low mortality, and stability of cardiac function. Subsequent pregnancies had no significant impact on their clinical course. During follow-up, cardiovascular comorbidities and medication use were documented for a substantial proportion of patients.</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"14 3","pages":"Article 102702"},"PeriodicalIF":11.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145274547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-11-07DOI: 10.1016/j.jchf.2025.102726
Zainali Chunawala MD , Kershaw V. Patel MD, MSCS , Katelyn R. Garcia MS , Matthew W. Segar MD, MS , Subodh Verma MD, PhD , Antoni Bayes-Genis MD, PhD , Rodica Pop-Busui MD, PhD , Deepak L. Bhatt MD, MPH, MBA , James L. Januzzi Jr. MD , Javed Butler MD , Carolyn S.P. Lam MBBS, PhD , Alain G. Bertoni MD, MPH , Mark Espeland PhD , Ambarish Pandey MD, MSCS
Background
N-terminal pro–B-type natriuretic peptide (NT-proBNP) identifies elevated risk for developing heart failure (HF) in type 2 diabetes (T2D). Whether risk of HF subtypes associated with NT-proBNP is modifiable with an intensive lifestyle intervention (ILI) targeting weight loss is unknown.
Objectives
This study aims to evaluate the association of baseline and longitudinal changes in NT-proBNP with risk of HF subtypes in T2D. In addition, we assessed whether NT-proBNP modified the association of an ILI with risk of HF subtypes.
Methods
Adults with T2D and overweight or obesity in the Look AHEAD trial were included (n = 3,959). Associations of baseline and 1-year changes in NT-proBNP with risk of HF subtypes (left ventricular ejection fraction ≥50% [heart failure with preserved ejection fraction (HFpEF)] and <50% (heart failure with reduced ejection fraction (HFrEF)] were evaluated in adjusted Cox models. Multiplicative interaction testing was performed to evaluate heterogeneous treatment effects of the ILI on HF subtypes across NT-proBNP concentrations.
Results
Elevated NT-proBNP (≥125 pg/mL) at baseline and increasing NT-proBNP over 1-year follow-up (vs stable or decreasing) were each significantly associated with higher risk of both HF subtypes. The ILI was associated with lower HFpEF risk among participants with elevated but not nonelevated baseline NT-proBNP (HRs for ILI vs diabetes support and education (DSE): HR: 0.47 (95% CI: 0.24-0.90) and HR: 1.65 (95% CI: 0.93-2.91), respectively; P for interaction = 0.003). Participants with stable or decreasing, but not increasing, NT-proBNP at 1-year follow-up had lower HFpEF risk with the ILI (HRs for ILI vs DSE: HR: 0.58 (95% CI: 0.34-0.99) and HR: 1.48 (95% CI: 0.61-3.56), respectively; P for interaction = 0.01). The ILI was not significantly associated with HFrEF risk across baseline or 1-year change in NT-proBNP categories.
Conclusions
In T2D, NT-proBNP can inform HF risk assessment and identify individuals who are more likely to benefit from an ILI. (Look AHEAD: Action for Health in Diabetes [Look AHEAD]; NCT00017953)
{"title":"Cardiac Biomarkers, Intensive Lifestyle Intervention, and Heart Failure Subtypes in Diabetes","authors":"Zainali Chunawala MD , Kershaw V. Patel MD, MSCS , Katelyn R. Garcia MS , Matthew W. Segar MD, MS , Subodh Verma MD, PhD , Antoni Bayes-Genis MD, PhD , Rodica Pop-Busui MD, PhD , Deepak L. Bhatt MD, MPH, MBA , James L. Januzzi Jr. MD , Javed Butler MD , Carolyn S.P. Lam MBBS, PhD , Alain G. Bertoni MD, MPH , Mark Espeland PhD , Ambarish Pandey MD, MSCS","doi":"10.1016/j.jchf.2025.102726","DOIUrl":"10.1016/j.jchf.2025.102726","url":null,"abstract":"<div><h3>Background</h3><div>N-terminal pro–B-type natriuretic peptide (NT-proBNP) identifies elevated risk for developing heart failure (HF) in type 2 diabetes (T2D). Whether risk of HF subtypes associated with NT-proBNP is modifiable with an intensive lifestyle intervention (ILI) targeting weight loss is unknown.</div></div><div><h3>Objectives</h3><div>This study aims to evaluate the association of baseline and longitudinal changes in NT-proBNP with risk of HF subtypes in T2D. In addition, we assessed whether NT-proBNP modified the association of an ILI with risk of HF subtypes.</div></div><div><h3>Methods</h3><div>Adults with T2D and overweight or obesity in the Look AHEAD trial were included (n = 3,959). Associations of baseline and 1-year changes in NT-proBNP with risk of HF subtypes (left ventricular ejection fraction ≥50% [heart failure with preserved ejection fraction (HFpEF)] and <50% (heart failure with reduced ejection fraction (HFrEF)] were evaluated in adjusted Cox models. Multiplicative interaction testing was performed to evaluate heterogeneous treatment effects of the ILI on HF subtypes across NT-proBNP concentrations.</div></div><div><h3>Results</h3><div>Elevated NT-proBNP (≥125 pg/mL) at baseline and increasing NT-proBNP over 1-year follow-up (vs stable or decreasing) were each significantly associated with higher risk of both HF subtypes. The ILI was associated with lower HFpEF risk among participants with elevated but not nonelevated baseline NT-proBNP (HRs for ILI vs diabetes support and education (DSE): HR: 0.47 (95% CI: 0.24-0.90) and HR: 1.65 (95% CI: 0.93-2.91), respectively; <em>P</em> for interaction = 0.003). Participants with stable or decreasing, but not increasing, NT-proBNP at 1-year follow-up had lower HFpEF risk with the ILI (HRs for ILI vs DSE: HR: 0.58 (95% CI: 0.34-0.99) and HR: 1.48 (95% CI: 0.61-3.56), respectively; <em>P</em> for interaction = 0.01). The ILI was not significantly associated with HFrEF risk across baseline or 1-year change in NT-proBNP categories.</div></div><div><h3>Conclusions</h3><div>In T2D, NT-proBNP can inform HF risk assessment and identify individuals who are more likely to benefit from an ILI. (Look AHEAD: Action for Health in Diabetes [Look AHEAD]; <span><span>NCT00017953</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"14 3","pages":"Article 102726"},"PeriodicalIF":11.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145461313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2025-12-05DOI: 10.1016/j.jchf.2025.102781
Kimberly Lamberti PhD , Jonathan Grinstein MD
{"title":"Practical Application of Pressure-Volume Loops and Cardiac Energetics to Improve Care Delivery in Pulmonary Hypertension","authors":"Kimberly Lamberti PhD , Jonathan Grinstein MD","doi":"10.1016/j.jchf.2025.102781","DOIUrl":"10.1016/j.jchf.2025.102781","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"14 3","pages":"Article 102781"},"PeriodicalIF":11.8,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145680600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-20DOI: 10.1016/j.jchf.2026.102990
Lee R Goldberg
{"title":"Association Without Causation: The Complex Relationship Between Sleep Disordered Breathing and Cardiovascular Disease.","authors":"Lee R Goldberg","doi":"10.1016/j.jchf.2026.102990","DOIUrl":"https://doi.org/10.1016/j.jchf.2026.102990","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":" ","pages":"102990"},"PeriodicalIF":11.8,"publicationDate":"2026-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147354909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-20DOI: 10.1016/j.jchf.2026.102995
Ezequiel J Molina, Francis D Pagani, Sean Pinney
{"title":"Rethinking Lifelong Management of Heart Failure Care in Young Adults: Is LVAD First, Transplant Later the Right Approach?","authors":"Ezequiel J Molina, Francis D Pagani, Sean Pinney","doi":"10.1016/j.jchf.2026.102995","DOIUrl":"https://doi.org/10.1016/j.jchf.2026.102995","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":" ","pages":"102995"},"PeriodicalIF":11.8,"publicationDate":"2026-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146258211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-12DOI: 10.1016/j.jchf.2025.102847
Jason L Guichard, Eric L Bonno, Michael E Nassif, Taiyeb M Khumri, David Miranda, Orvar Jonsson, Hirak Shah, Tamas Alexy, Gregory P Macaluso, James Sur, Gavin Hickey, Patrick McCann, Jennifer A Cowger, Amit Badiye, Wayne D Old, Yasmin Raza, Luke Masha, Chandra Kunavarapu, Mosi Bennett, Faisal Sharif, Michael Kiernan, Wilfried Mullens, Sandra V Chaparro, Claudius Mahr, Rohit R Amin, Nicholas J Hiivala, Max M Owens, Andrea Sauerland, Omid Forouzan, Liviu Klein
Background: In the PROACTIVE-HF (A Prospective, Multi-Center, Open Label, Single Arm Clinical Trial Evaluating the Safety and Efficacy of the Cordella Pulmonary Artery Sensor System in NYHA Class III Heart Failure Patients) trial, remote heart failure (HF) management using seated mean pulmonary artery pressure (mPAP) and vital signs was safe and resulted in a low rate of HF hospitalizations and mortality through 6 months.
Objectives: The authors evaluated the effect of managing seated mPAP with the Cordella system on outcomes in patients with HF through 12 months.
Methods: In a single-arm, open-label trial, conducted in 75 European and U.S. centers, the authors enrolled HF patients with NYHA functional class III symptoms, irrespective of ejection fraction, and recent HF hospitalization and/or elevated natriuretic peptides. The prespecified, powered, secondary effectiveness endpoint at 12 months required the HF hospitalization or all-cause mortality rate to be lower than a performance goal of 0.70 events/patient/12 months, established from previous hemodynamic monitoring trials. Device/system-related complications, pressure sensor failure, and serious adverse events were examined.
Results: Between February 7, 2020, and March 31, 2023, 456 patients were implanted in a modified intent-to-treat cohort. The 12-month event rate was 0.36 (95% CI: 0.31-0.42), which was significantly lower than the performance goal (0.36 vs 0.70; P < 0.0001). There were no device/system-related complications or pressure sensor failures beyond the 6-month primary results (0.8% and 0.2%, respectively).
Conclusions: Remote HF management using seated mPAP and vital signs in NYHA functional class III patients is safe and results in a low rate of HF hospitalizations and mortality over 12 months. These results support the use of seated mPAP monitoring and extend the evidence that pulmonary artery pressure-guided management improves HF outcomes. (A Prospective, Multi-Center, Open Label, Single Arm Clinical Trial Evaluating the Safety and Efficacy of the Cordella Pulmonary Artery Sensor System in NYHA Class III Heart Failure Patients [PROACTIVE-HF Trial]; NCT04089059).
背景：在PROACTIVE-HF（一项前瞻性、多中心、开放标签、单臂临床试验，评估Cordella肺动脉传感器系统在NYHA III类心力衰竭患者中的安全性和有效性）试验中，使用坐位平均肺动脉压（mPAP）和生命体征进行远程心力衰竭（HF）管理是安全的，并且在6个月内HF住院率和死亡率较低。目的：作者评估了使用Cordella系统管理坐式mPAP对HF患者12个月预后的影响。方法：在一项在75个欧洲和美国中心进行的单臂、开放标签试验中，作者招募了具有NYHA功能III级症状的HF患者，无论射血分数如何，近期HF住院和/或利钠肽升高。预先指定的次要有效性终点在12个月时要求HF住院率或全因死亡率低于0.70事件/患者/12个月的性能目标，该目标是由先前的血流动力学监测试验建立的。检查了设备/系统相关并发症、压力传感器失效和严重不良事件。结果：在2020年2月7日至2023年3月31日期间，在修改的意向治疗队列中植入了456名患者。12个月事件发生率为0.36 (95% CI: 0.31-0.42)，显著低于性能目标（0.36 vs 0.70; P < 0.0001）。在6个月的初步结果之后，没有器械/系统相关的并发症或压力传感器故障（分别为0.8%和0.2%）。结论：在NYHA功能III级患者中，使用坐式mPAP和生命体征进行HF远程管理是安全的，并且在12个月内HF住院率和死亡率较低。这些结果支持坐式mPAP监测的使用，并扩展了肺动脉压力引导管理改善心衰结局的证据。一项前瞻性、多中心、开放标签、单臂临床试验，评估Cordella肺动脉传感器系统在NYHA III级心力衰竭患者中的安全性和有效性[PROACTIVE-HF试验]；NCT04089059)。
{"title":"Seated Pulmonary Artery Pressure Management in Patients With Heart Failure: 12-Month Outcomes of the PROACTIVE-HF Trial.","authors":"Jason L Guichard, Eric L Bonno, Michael E Nassif, Taiyeb M Khumri, David Miranda, Orvar Jonsson, Hirak Shah, Tamas Alexy, Gregory P Macaluso, James Sur, Gavin Hickey, Patrick McCann, Jennifer A Cowger, Amit Badiye, Wayne D Old, Yasmin Raza, Luke Masha, Chandra Kunavarapu, Mosi Bennett, Faisal Sharif, Michael Kiernan, Wilfried Mullens, Sandra V Chaparro, Claudius Mahr, Rohit R Amin, Nicholas J Hiivala, Max M Owens, Andrea Sauerland, Omid Forouzan, Liviu Klein","doi":"10.1016/j.jchf.2025.102847","DOIUrl":"https://doi.org/10.1016/j.jchf.2025.102847","url":null,"abstract":"<p><strong>Background: </strong>In the PROACTIVE-HF (A Prospective, Multi-Center, Open Label, Single Arm Clinical Trial Evaluating the Safety and Efficacy of the Cordella Pulmonary Artery Sensor System in NYHA Class III Heart Failure Patients) trial, remote heart failure (HF) management using seated mean pulmonary artery pressure (mPAP) and vital signs was safe and resulted in a low rate of HF hospitalizations and mortality through 6 months.</p><p><strong>Objectives: </strong>The authors evaluated the effect of managing seated mPAP with the Cordella system on outcomes in patients with HF through 12 months.</p><p><strong>Methods: </strong>In a single-arm, open-label trial, conducted in 75 European and U.S. centers, the authors enrolled HF patients with NYHA functional class III symptoms, irrespective of ejection fraction, and recent HF hospitalization and/or elevated natriuretic peptides. The prespecified, powered, secondary effectiveness endpoint at 12 months required the HF hospitalization or all-cause mortality rate to be lower than a performance goal of 0.70 events/patient/12 months, established from previous hemodynamic monitoring trials. Device/system-related complications, pressure sensor failure, and serious adverse events were examined.</p><p><strong>Results: </strong>Between February 7, 2020, and March 31, 2023, 456 patients were implanted in a modified intent-to-treat cohort. The 12-month event rate was 0.36 (95% CI: 0.31-0.42), which was significantly lower than the performance goal (0.36 vs 0.70; P < 0.0001). There were no device/system-related complications or pressure sensor failures beyond the 6-month primary results (0.8% and 0.2%, respectively).</p><p><strong>Conclusions: </strong>Remote HF management using seated mPAP and vital signs in NYHA functional class III patients is safe and results in a low rate of HF hospitalizations and mortality over 12 months. These results support the use of seated mPAP monitoring and extend the evidence that pulmonary artery pressure-guided management improves HF outcomes. (A Prospective, Multi-Center, Open Label, Single Arm Clinical Trial Evaluating the Safety and Efficacy of the Cordella Pulmonary Artery Sensor System in NYHA Class III Heart Failure Patients [PROACTIVE-HF Trial]; NCT04089059).</p>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":" ","pages":"102847"},"PeriodicalIF":11.8,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146179958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号